Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX0035 in Early Alzheimer's Disease (PEGASUS)
NCT03533257Phase 2Completed
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Sep 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium phenylbutyrate in Alzheimer's disease (AD) (2 arms), sponsored by Amylyx Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at 24 weeks and Global Composite Statistical Test at 24 weeks. Started Sep 2018; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03533257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533257.